Prosecution Insights
Last updated: October 25, 2026

K&L Gates LLP - Gambro

Technology areas: Chemistry & Materials • Medical Devices & Mechanical Engineering

12 pending office actions • 2 clients • 12 examiners • 9 art units • 0 of 12 (0%) have an AI response strategy ready • 19 patents granted in the last 365 days

Analysis

K&L Gates LLP - Gambro has 11 pending office actions in Chemistry & Materials. The profile also records 34332 career applications, an 84.49% resolved allowance rate, and 3.82 average office actions per allowance. These measures place the client-linked workload within a broader prosecution record.

The pending-action figure concerns current matters, while the remaining metrics describe historical activity associated with the record. The allowance rate is not an individual-case forecast, and the office-action average indicates repeated examination activity before allowance in the resolved set. Practitioners should use the data to support workload planning while evaluating chemical and materials issues on the facts of each application.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Quality Metrics (n=34332 apps, methodology: how we score firms)

84.5%
Allowance Rate
n=34332
+0.65σ
Allowance Rate (norm)
n=34332
3.8
OAs to Allowance
n=20756
+0.02σ
OAs to Allow (norm)
n=20756
1083 days
Time to Allowance
n=20756
+9.0pp
Interview Lift
n=34332
32.5%
RCE Rate
n=34332
2.7%
Appeal Rate
n=34332

Rejection Performance (% of received rejections ultimately overcome)

76.3%
§101 Overcome
n=2444
77.1%
§102 Overcome
n=9062
77.7%
§103 Overcome
n=15328
77.8%
§112 Overcome
n=10507

Specialization & Scale

A61K, H01M, G06F
Top CPC Subclasses
13%
Top-3 CPC Share
n=34332
90
Practitioners
n=34332
381.5
Apps / Practitioner
n=34332

Portfolio Summary

12
Total Pending OAs
6
Non-Final OAs
5
Final Rejections
1
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

1
Overdue
0
Due this week
1
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

6
Hard (50%)
4
Medium (33%)
2
Easy (17%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 only2 (17%)
§101 + other1 (8%)
§103 only3 (25%)
§102 only1 (8%)
§112 only2 (17%)
Multi-statute (no §101)3 (25%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

6
Life Sciences
50% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
6
Mechanical / Eng
50% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

120 h
Manual time on pending OAs
24 h
Time saved (low, 20%)
42 h
Time saved (mid, 35%)
1.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
SPAMER, DONALD R 1 59.4% +32.3%
LUCCHESI, NICHOLAS D 1 78.4% +9.5%
MPAMUGO, CHINYERE 1 28.9% +26.9%
BARSKY, JARED 1 50.3% +22.8%
STIGELL, THEODORE J 1 78.3% +14.8%
KURTZ, BENJAMIN M 1 56.7% +17.7%
FITZSIMMONS, ALLISON G 1 48.1% +16.0%
MCGANN, BERNADETTE KAREN 1 64.1% +18.0%
NEWTON, CHAD A 1 38.4% +23.4%
PEO, JONATHAN M 1 48.4% +47.6%

Hard Cases (6)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.

App #TitleExaminerDue in
18721129 MEDICAL DEVICE INTEROPERABILITY METHODS, APPARATUS, AND SYSTEM MPAMUGO, CHINYERE 26d overdue
18030116 ESTIMATING RESIDUAL RENAL FUNCTION NEWTON, CHAD A 29d
18711827 DIALYSIS FLUID COMPRISING KETONE BODIES FOR THE TREATMENT OF CANCER BARSKY, JARED —
18709360 PERITONEAL DIALYSIS SYSTEM HAVING A CAPILLARY PATIENT LINE FILTER STIGELL, THEODORE J —
18572121 ACIDIC AND ALKALINE CLEANING OF ION EXCHANGE SYSTEMS, SUCH AS WATER PURIFIERS, BY ION EXCHANGE RESIN FITZSIMMONS, ALLISON G —
17757266 FLUID DIVERTING DEVICE FOR AN APPARATUS FOR EXTRACORPOREAL TREATMENT OF BLOOD AND BLOOD SET PROVIDED WITH SAID FLUID DIVERTING DEVICE ARBLE, JESSICA R —

Interview Candidates (9)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
18721129 MEDICAL DEVICE INTEROPERABILITY METHODS, APPARATUS, AND SYSTEM MPAMUGO, CHINYERE 26d overdue
18030116 ESTIMATING RESIDUAL RENAL FUNCTION NEWTON, CHAD A 29d
18872148 DEVICE FOR DISINFECTING AND CLEANING A CATHETER, AND A METHOD THEREOF SPAMER, DONALD R —
18711827 DIALYSIS FLUID COMPRISING KETONE BODIES FOR THE TREATMENT OF CANCER BARSKY, JARED —
18709360 PERITONEAL DIALYSIS SYSTEM HAVING A CAPILLARY PATIENT LINE FILTER STIGELL, THEODORE J —
18608304 PREPARING AN EXTRACORPOREAL BLOOD TREATMENT APPARATUS KURTZ, BENJAMIN M —
18572121 ACIDIC AND ALKALINE CLEANING OF ION EXCHANGE SYSTEMS, SUCH AS WATER PURIFIERS, BY ION EXCHANGE RESIN FITZSIMMONS, ALLISON G —
18554418 APPARATUS AND METHODS FOR EFFICIENT PRODUCTION OF DIALYSIS FLUID USING FORWARD OSMOSIS MCGANN, BERNADETTE KAREN —

Client Portfolio (2 clients)

Client (Assignee)Pending OAs
Baxter 11
Baxter Healthcare S.A. 1

Top Art Units

Art UnitApps
17792
17732
37812
17991
37721
36851
16281
37831
36811

Pending Office Actions

App #TitleClientExaminerArt UnitStatutesStatusDue inAIFiled
18872148 DEVICE FOR DISINFECTING AND CLEANING A CATHETER, AND A METHOD THEREOF Gambro Lundia AB SPAMER, DONALD R 1799 §112 Non-Final OA — Pending Dec 05, 2024
18844270 GENERATING MEDICAL FLUID FOR RENAL REPLACEMENT THERAPY Gambro Lundia AB LUCCHESI, NICHOLAS D 3772 §112 Non-Final OA — Pending Sep 05, 2024
18721129 MEDICAL DEVICE INTEROPERABILITY METHODS, APPARATUS, AND SYSTEM Gambro Lundia AB MPAMUGO, CHINYERE 3685 §101 Final Rejection 26d overdue Pending Jun 17, 2024
18711827 DIALYSIS FLUID COMPRISING KETONE BODIES FOR THE TREATMENT OF CANCER Gambro Lundia AB BARSKY, JARED 1628 §101§103 Final Rejection — Pending May 20, 2024
18709360 PERITONEAL DIALYSIS SYSTEM HAVING A CAPILLARY PATIENT LINE FILTER BAXTER HEALTHCARE SA STIGELL, THEODORE J 3783 §102§103 Non-Final OA — Pending May 10, 2024
18608304 PREPARING AN EXTRACORPOREAL BLOOD TREATMENT APPARATUS Gambro Lundia AB KURTZ, BENJAMIN M 1779 §102 Final Rejection — Pending Mar 18, 2024
18572121 ACIDIC AND ALKALINE CLEANING OF ION EXCHANGE SYSTEMS, SUCH AS WATER PURIFIERS, BY ION EXCHANGE RESIN Gambro Lundia AB FITZSIMMONS, ALLISON G 1773 §102§103§112 Non-Final OA — Pending Dec 19, 2023
18554418 APPARATUS AND METHODS FOR EFFICIENT PRODUCTION OF DIALYSIS FLUID USING FORWARD OSMOSIS Gambro Lundia AB MCGANN, BERNADETTE KAREN 1773 §103 Final Rejection — Pending Oct 06, 2023
18030116 ESTIMATING RESIDUAL RENAL FUNCTION Gambro Lundia AB NEWTON, CHAD A 3681 §101 Non-Final OA 29d Pending Apr 04, 2023
18108091 PACKAGE FOR AN ACIDIC DIALYSIS FLUID CONCENTRATE CONTAINING CITRATE AND GLUCOSE Gambro Lundia AB PEO, JONATHAN M 1779 §103 Non-Final OA — Pending Feb 10, 2023
17757266 FLUID DIVERTING DEVICE FOR AN APPARATUS FOR EXTRACORPOREAL TREATMENT OF BLOOD AND BLOOD SET PROVIDED WITH SAID FLUID DIVERTING DEVICE Gambro Lundia AB ARBLE, JESSICA R 3781 §102§103§112 Non-Final OA — Pending Jun 13, 2022
17634855 NON-REMOVABLE CONNECTION SYSTEM Gambro Lundia AB LE, QUYNH DAO 3781 §103 Final Rejection — Pending Feb 11, 2022

Managing K&L Gates LLP - Gambro's Patent Prosecution?

IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

What is K&L Gates LLP - Gambro's patent allowance rate?

84.5% of resolved applications prosecuted by K&L Gates LLP - Gambro were allowed, across 34,332 applications in USPTO records.

How many office actions does K&L Gates LLP - Gambro average before allowance?

3.82 office actions per allowed application on average.

How many pending office actions does K&L Gates LLP - Gambro have?

12 pending office actions as of October 2026, for 2 clients, before 12 examiners in 9 art units.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month